China has become the first country to green-light an inhaled Covid-19 vaccine, paving the way for potential use of the needle-free product in the country, where suppressing the spread of Covid-19 remains a top priority
The vaccine maker, CanSino Biologics, said in a statement Sunday that China's medicines regulator had approved the inhaled dose for emergency use as a booster vaccine. The product, known as Convidecia Air, delivers a vaccine dose through a puff of air from a nebulizer that is then inhaled by mouth. CanSino's injected Convidecia Covid-19 vaccine is already in use in China and has been approved in a handful of other countries.
CanSino cautioned in a company filing that some regulatory steps remain before the vaccine can go to market, and said its product would face"fierce competition" domestically, where nine vaccines have so far received authorization.In a news release, CanSino said Convidecia Air"can induce strong humoral, cellular and mucosal immunity."The manufacturer didn't provide data to support those claims, but referred to studies in The Lancet medical journal.
Indonesia Berita Terbaru, Indonesia Berita utama
Similar News:Anda juga dapat membaca berita serupa dengan ini yang kami kumpulkan dari sumber berita lain.
The World's First Needle-Free COVID Vaccine Just Got Approved in ChinaJust one breath of a vaccine mist can provide strong immune protection against COVID-19, vaccine maker CanSino said in a news release Sunday (Sept.
Baca lebih lajut »
China approves inhaled Covid vaccineInhaled as a fine mist, Convidecia Air can provide good protection after just one breath, its maker says.
Baca lebih lajut »
Parts of China re-enter COVID-19 lockdown days before holiday travelIt said that outbreaks have been reported in 103 cities, the highest since the early days of the pandemic in early 2020.
Baca lebih lajut »
Parts of China re-enter COVID-19 lockdown days before holiday travelIt said that outbreaks have been reported in 103 cities, the highest since the early days of the pandemic in early 2020.
Baca lebih lajut »